First China weight loss drug emerges
Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China.
Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation.
With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy.
China's nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year. While China still accounts for just a fraction of the projected US$150 billion global pie, a raft of homegrown treatments and cheaper generics could significantly improve the availability – and affordability – of the medication.
The country has a pipeline of more than 30 late-stage obesity drug candidates under development, according to LEK Consulting. Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country.
Local biotech firms are promising to overcome the limitations of current treatments, including creating long-awaited GLP-1 pills that are just as effective and safe as weekly injections peddled by Novo and Lilly.
Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be taken every two weeks, instead of weekly. Laekna is developing a treatment that would help patients preserve more muscle – a common concern among GLP-1 takers – while still losing fat. Hangzhou Sciwind Biosciences expects China will approve its drug ecnoglutide, which led to more than 15 per cent weight loss after 48 weeks when given at the highest dose, in early 2026.
'Multiple Chinese biopharma are developing differentiated and competitive candidates and have the potential to lead the direction of weight loss drug research and development,' said Chen Chen, head of China healthcare research at UBS Securities.
Competition is expected to ramp up next year when cheaper alternative versions of semaglutide – the active ingredient in Novo's Wegovy – launch after semaglutide's China patent expires. Their emergence could pressure drugmakers to lower their treatment prices, and could quickly expand access to the drugs across a country of 1.4 billion people.
Compared to Western countries where popular GLP-1 drugs are widely available for people looking to lose weight, the current penetration rate for such drugs in China is 'extremely low,' said UBS's Mr Chen. Novo only started rolling out obesity treatments in China in 2024, and Lilly earlier this year.
A government-led campaign to curb obesity and establish new weight management clinics has fuelled demand, which is now outstripping supply and leading to stock shortages, said Shawn Qu, chief of SinoUnited Health's Endocrinology, Metabolism and Thyroid Center in Shanghai.
'It's far from meeting the clinical need,' said Mr Qu, who's also an adviser to China's National Health Commission weight management committee.
Foreign medicines have long enjoyed higher trust and recognition in China, where the local biotech industry is still overcoming past quality issues.
Skepticism about the quality of domestic generic medicines also remains high among Chinese – and rare backlash from doctors earlier this year fuelled questions about whether government efforts to slash treatment prices had come at the cost of efficacy.
The relative price differences between foreign and domestic weight loss drugs could be much smaller than in PD-(L)1 medicines used to treat cancer, added Yang Huang, senior analyst for China healthcare research at JP Morgan.
'We think foreign companies could be more willing to lower prices for their weight loss drugs in China,' he said, 'as we have seen in the US market where major weight loss drug players have started engaging in price competition.'
Going forward, 'you'll see a lot more competitors in the China market versus anywhere else,' said Justin Wang, head of LEK's China practice. 'It will be unlikely for one or two companies to dominate the whole market.' BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
9 hours ago
- Straits Times
NGOs urge end to US-backed Gaza aid distribution system
The non-governmental organisations urged a return to the UN-led aid mechanism that existed in the war-torn territory until March. PHOTO: AFP JERUSALEM - A group of 169 aid organisations called for an end to a US- and Israeli-backed aid distribution scheme in Gaza after repeated reports of people being killed while seeking rations. The non-governmental organisations urged a return to the UN-led aid mechanism that existed in the war-torn territory until March, when Israel imposed a full blockade on humanitarian assistance entering Gaza during an impasse in truce talks with Palestinian militant group Hamas. 'NGOs call for immediate action to end the deadly Israeli distribution scheme (including the so-called Gaza Humanitarian Foundation) in Gaza,' the organisations wrote in a joint statement on June 30 . They urged action to 'revert to the existing UN-led coordination mechanisms, and lift the Israeli government's blockade on aid and commercial supplies'. The US- and Israeli-backed Gaza Humanitarian Foundation (GHF) has been tasked with distributing aid in the Palestinian territory since late May, when the two-month blockade was partially eased after mounting international condemnation and warnings of imminent famine. GHF operations have since been marred by chaotic scenes and near-daily reports of Israeli forces firing on those waiting to collect rations in the territory, where the Israeli military is seeking to destroy Hamas. The signatories to the June 30 statement included NGOs from Europe, the United States and Israel working in medical assistance, hunger relief, development and human rights. They said more than 500 Palestinians were killed and almost 4,000 injured while trying to access or distribute food in less than four weeks. The Hamas-ruled territory's health ministry has given similar figures. 'Under the Israeli government's new scheme, starved and weakened civilians are being forced to trek for hours through dangerous terrain and active conflict zones, only to face a violent, chaotic race to reach fenced, militarised distribution sites,' the statement read. Aid distribution in Gaza was traditionally coordinated through various NGOs and UN agencies, notably the UN agency for Palestinian refugees UNRWA, which had 13,000 staff in the coastal enclave before the war. Israel said it tasked GHF with distribution in Gaza to keep Hamas from controlling the flow of aid. The Israeli military last week denied a newspaper report that cited Israeli soldiers as saying they had been ordered to fire at civilians near aid centres. It said in a statement that it was 'operating to allow and facilitate the distribution of humanitarian aid' by GHF, 'and to secure the routes leading to the distribution centers, in order to allow the aid to reach the civilians rather than Hamas'. It added that it was examining 'reports of incidents of harm to the civilians approaching the distribution centres'. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
Asia News Network
16 hours ago
- Asia News Network
Mental health problems growing among new mums in Nepal
July 1, 2025 KATHMANDU – A few weeks ago, a 26-year-old working class mother was rushed to the Thapathali-based Paropakar Maternity and Women's Hospital, as she suffered from persistent sadness, sleeplessness, and loss of interest in everything including her newborn. Doctors attending the patient identified that the woman was suffering from postpartum depression developed after the child birth. 'We prescribed anti-depressants to the patients, as she was suffering from anxiety and depression, which are serious mental health problems,' said Dr Pratikshya Ghimire, a psychiatrist at the hospital. 'The patient is recuperating now, as her family members and in-laws were supportive.' Every day, doctors at the maternity hospital refer to over half a dozen pregnant or postnatal women seeking care at the hospital for psychiatric and psychological counseling. Of those referred, the number of working class women is significant. However, not all women suffering from prenatal depression (depression during pregnancy) and postpartum depression (depression after child birth) get proper treatment like the woman mentioned above, as most birthing centers throughout the country lack mental health screening services. 'Health workers including physicians may ask pregnant and postnatal women they suspect have mental health issues for seeking psychiatric or psychological help, but all may not be able to afford,' said Ghimire. 'Thousands of women would benefit if mental health services were made available in maternity hospitals.' Studies show that working mothers are at greater risk for postpartum depression. Mental health problems during pregnancy are the second leading cause of maternal deaths, after excessive bleeding during childbirth, also known as postpartum haemorrhage, and pre-eclampsia (pregnancy-related high blood pressure disorders). A report on maternal mortality unveiled in 2022 by the National Statistics Office showed that six percent of maternal deaths were due to self-harm (suicide), with most cases occurring during pregnancy. To address mental health problems during pregnancy, the Ministry of Health and Population started outpatient care services at the Maternity Hospital in October last year with the help of the World Health Organisation. Health Officials had planned to expand such services to at least one hospital in each province. 'But due to the budget constraints, we could not expand the services this year,' said Dr Phadindra Baral, chief of the Mental Health Section at the Epidemiology and Disease Control Division. 'We are aware that the service is essential and thousands of pregnant and postnatal women throughout the country will be benefitted if we provide it.' Doctors say mental health problems in pregnant women and new mothers are more severe than previously believed, with around 20 percent women affected. They say prenatal and postnatal depression can occur at any time during pregnancy or after childbirth. Shifts in hormone levels during pregnancy and after childbirth can significantly affect mood. Many women feel anxious about changes happening to their bodies. Some may even have financial concerns and some worry about taking on new and additional responsibilities. Some women experience extreme sadness, anxiety, fatigue, and changes in sleeping and eating habits during pregnancy or after childbirth. Experts warn that prenatal and postnatal depression along with anxiety and other mental health issues, can lead some women to take their own lives. In the case mentioned above, the woman worried excessively about her job, career, and future of the baby. She feared that she could not resume her job again, which not only increased her family's financial troubles but also affected her career and the future of her newborn. After treatment, her condition is getting better every day. 'We will adjust doses of her medicines in the coming days,' said Ghimire. Health officials hope that screening pregnant women for mental health problems and providing prompt treatment will help reduce maternal deaths, which have been rising alarmingly of late. Nepal reduced the maternal mortality rate from 539 per 100,000 births in 1996 to 239 per 100,000 births in 2016. For this, the country also received a Millennium Development Goals award. The 2021 census report showed that in every 100,000 live births, 151 women died from maternity-related complications. A recent report by the UN health body shows that Nepal has reduced maternal deaths by over 70 percent since 2000. The UN health body, in its report stated that currently 142 Nepali women die from maternity-related complications per 100,0000 live births. Nepal's target under the UN's Sustainable Development Goals is to reduce the maternal mortality rate to 75 per 100,000 births by 2030.
Straits Times
2 days ago
- Straits Times
First China weight loss drug emerges
Obesity drugmakers Novo Nordisk and Eli Lilly & Co. now face their first serious rival in China. PHOTO: REUTERS Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy. China's nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year. While China still accounts for just a fraction of the projected US$150 billion global pie, a raft of homegrown treatments and cheaper generics could significantly improve the availability – and affordability – of the medication. The country has a pipeline of more than 30 late-stage obesity drug candidates under development, according to LEK Consulting. Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country. Local biotech firms are promising to overcome the limitations of current treatments, including creating long-awaited GLP-1 pills that are just as effective and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be taken every two weeks, instead of weekly. Laekna is developing a treatment that would help patients preserve more muscle – a common concern among GLP-1 takers – while still losing fat. Hangzhou Sciwind Biosciences expects China will approve its drug ecnoglutide, which led to more than 15 per cent weight loss after 48 weeks when given at the highest dose, in early 2026. 'Multiple Chinese biopharma are developing differentiated and competitive candidates and have the potential to lead the direction of weight loss drug research and development,' said Chen Chen, head of China healthcare research at UBS Securities. Competition is expected to ramp up next year when cheaper alternative versions of semaglutide – the active ingredient in Novo's Wegovy – launch after semaglutide's China patent expires. Their emergence could pressure drugmakers to lower their treatment prices, and could quickly expand access to the drugs across a country of 1.4 billion people. Compared to Western countries where popular GLP-1 drugs are widely available for people looking to lose weight, the current penetration rate for such drugs in China is 'extremely low,' said UBS's Mr Chen. Novo only started rolling out obesity treatments in China in 2024, and Lilly earlier this year. A government-led campaign to curb obesity and establish new weight management clinics has fuelled demand, which is now outstripping supply and leading to stock shortages, said Shawn Qu, chief of SinoUnited Health's Endocrinology, Metabolism and Thyroid Center in Shanghai. 'It's far from meeting the clinical need,' said Mr Qu, who's also an adviser to China's National Health Commission weight management committee. Foreign medicines have long enjoyed higher trust and recognition in China, where the local biotech industry is still overcoming past quality issues. Skepticism about the quality of domestic generic medicines also remains high among Chinese – and rare backlash from doctors earlier this year fuelled questions about whether government efforts to slash treatment prices had come at the cost of efficacy. The relative price differences between foreign and domestic weight loss drugs could be much smaller than in PD-(L)1 medicines used to treat cancer, added Yang Huang, senior analyst for China healthcare research at JP Morgan. 'We think foreign companies could be more willing to lower prices for their weight loss drugs in China,' he said, 'as we have seen in the US market where major weight loss drug players have started engaging in price competition.' Going forward, 'you'll see a lot more competitors in the China market versus anywhere else,' said Justin Wang, head of LEK's China practice. 'It will be unlikely for one or two companies to dominate the whole market.' BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
